» Articles » PMID: 35646819

Multifunctional Anti-Alzheimer's Disease Effects of Natural Xanthone Derivatives: A Primary Structure-Activity Evaluation

Overview
Journal Front Chem
Specialty Chemistry
Date 2022 Jun 1
PMID 35646819
Authors
Affiliations
Soon will be listed here.
Abstract

A series of α-Mangostin (α-M) derivatives were designed and synthesized. α-M and four analogues were evaluated for their multifunctional anti-Alzheimer's disease (anti-AD) effects on fibrillogenesis, microglial uptake, microglial degradation, and anti-neurotoxicity of Aβ, as well as LPS-induced neuroinflammation. The differences in bioactivities were analyzed to understand the structure-activity relationship for further modifications. This study aims to investigate the anti-AD effects of α-M and elucidate its structure-activity relationship by comparing difference between α-M and several analogues. Aβ fibrillogenesis was detected by Thioflavin T fluorometric assay. The levels of Aβ and inflammatory cytokines were evaluated by enzyme-linked immunosorbent assay. Neuron viability was examined by the CCK-8 assay. The morphology of ZO-1 of bEnd.3 cultured in BV-2-conditioned medium was evaluated by immunofluorescence staining. Aβ fibrillogenesis was significantly inhibited by co-incubation with α-M, Zcbd- or Zcbd-. α-M, Zcbd-, Zcbd- and Zcbd- decreased the levels of Aβ and inflammatory cytokines, and promoted Aβ uptake, degradation and anti-inflammation effects inflammation in microglia. α-M and Zcbd- protected neuron viability from Aβ-induced neurotoxicity, and preserved tight junction integrity of bEnd.3 against LPS-induced neuroinflammation. Zcbd- acted as α-M almost in all effects. The structure-activity analysis indicated that the 3-methyl-2-butenyl group at C-8 is essential for the bioactivity of α-M, while modifying the double hydroxylation at the C-2 position may improve the multifunctional anti-AD effects.

Citing Articles

The Effects and Mechanisms of Xanthones in Alzheimer's Disease: A Systematic Review.

Pang L, Hamzah S, Tan S, Mah S, Yow H Neurochem Res. 2023; 48(12):3485-3511.

PMID: 37578655 DOI: 10.1007/s11064-023-04005-8.


An overview of structure-based activity outcomes of pyran derivatives against Alzheimer's disease.

Almalki F Saudi Pharm J. 2023; 31(6):998-1018.

PMID: 37234350 PMC: 10205782. DOI: 10.1016/j.jsps.2023.04.030.


Polyphenols: Natural food grade biomolecules for treating neurodegenerative diseases from a multi-target perspective.

Li Z, Zhao T, Shi M, Wei Y, Huang X, Shen J Front Nutr. 2023; 10:1139558.

PMID: 36925964 PMC: 10011110. DOI: 10.3389/fnut.2023.1139558.


Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer's Disease.

Deng M, Yan W, Gu Z, Li Y, Chen L, He B Molecules. 2023; 28(3).

PMID: 36771152 PMC: 9920976. DOI: 10.3390/molecules28031486.


Honokiol and Alpha-Mangostin Inhibit Mayaro Virus Replication through Different Mechanisms.

Valdes-Torres P, Campos D, Bhakta M, Galan-Jurado P, Durant-Archibold A, Gonzalez-Santamaria J Molecules. 2022; 27(21).

PMID: 36364188 PMC: 9659048. DOI: 10.3390/molecules27217362.

References
1.
Thurgur H, Pinteaux E . Microglia in the Neurovascular Unit: Blood-Brain Barrier-microglia Interactions After Central Nervous System Disorders. Neuroscience. 2019; 405:55-67. DOI: 10.1016/j.neuroscience.2018.06.046. View

2.
Hardy J, Selkoe D . The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580):353-6. DOI: 10.1126/science.1072994. View

3.
Gouras G, Olsson T, Hansson O . β-Amyloid peptides and amyloid plaques in Alzheimer's disease. Neurotherapeutics. 2014; 12(1):3-11. PMC: 4322079. DOI: 10.1007/s13311-014-0313-y. View

4.
Phillips J . Why Aβ42 Is Much More Toxic than Aβ40. ACS Chem Neurosci. 2019; 10(6):2843-2847. DOI: 10.1021/acschemneuro.9b00068. View

5.
Colonna M, Butovsky O . Microglia Function in the Central Nervous System During Health and Neurodegeneration. Annu Rev Immunol. 2017; 35:441-468. PMC: 8167938. DOI: 10.1146/annurev-immunol-051116-052358. View